NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Complete Abstract Language:

The present disclosure provides compositions and in vitro or ex vivo methods for obtaining an enhanced antigen specific Th1 immune response. The compositions can comprise activation enhanced dendritic cells or T cells produced in vitro. The methods comprise contacting immature dendritic cells with a maturation agent that comprises a dendritic cell maturation agent, interferon y and an inflammation-activating lipid which can produce hyperactivated dendritic cells. The method can further comprise contacting the maturing dendritic cells with a predetermined antigen during maturation. An in vitro or ex vivo method is also provided wherein the hyperactive dendritic cells can be used to induce naive T cell activation, where the activated T cells can be formulated for administration to an individual in need of such treatment. — NWBO patent application, first public April 15, 2021